Table 3.
Drug samples failing Raman spectrometry testsa
| Sampling | Older monotherapiesb |
Artemisinin monotherapies |
ACTc | Total Failuresd |
|---|---|---|---|---|
| Lagos 2007 | 3/6 | 3/7 | 1/7 | 7/20 |
| Lagos 2008 | 10/49 | 17/58 | 1/5 | 28/112 |
| Lagos 2010 | 8/28 | 7/44 | 1/15 | 16/87 |
| Lagos Total | 21/83 | 27/109 | 3/27 | 51/219 |
| Accra 2007 | 5/11 | 6/15 | 3/8 | 14/34 |
| Accra 2010 | 5/16 | 8/23 | 1/8 | 14/47 |
| Accra Total | 10/27 | 14/38 | 4/16 | 28/81 |
| TOTAL | 31/110 | 41/147 | 7/43 | 79/300 |
a. Numbers are total that failed testing/total samples tested
b. Includes amodiaquine, mefloquine or sulphadoxine-pyrimethamine
c. Artemisinin-based combination therapy
d. Only 88% of total samples were tested by spectrometry (300 out of 339), since the TruScan spectrometer requires a known good quality version for comparison and for 39 samples this could not be established.